Skip to main content
Triangle logo TriangleGet started

Azacitidine (NCT03683433)

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation: a one-minute explainerNCT036834331 min

Azacitidine trial for Acute Bilineal Leukemia (NCT03683433). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with IDH2-mutated AML or mixed-lineage leukemia after treatment failure. Newly diagnosed AML may qualify after MDS or CMML, or in people over 60 ineligible for intensive chemotherapy.

The idea: oral enasidenib blocks mutant IDH2, aiming to restore cell maturation. It joins azacitidine injections under the skin or into a vein on days one to seven. Cycles last four to six weeks. Researchers assess responses, survival and toxicity.

This phase 2 study plans 50 patients. Courtney DiNardo leads it at MD Anderson in Houston, the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.